These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 3875667

  • 1. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.
    Wallace RJ, Swenson JM, Silcox VA, Bullen MG.
    J Infect Dis; 1985 Sep; 152(3):500-14. PubMed ID: 3875667
    [Abstract] [Full Text] [Related]

  • 2. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei.
    Dalovisio JR, Pankey GA, Wallace RJ, Jones DB.
    Rev Infect Dis; 1981 Sep; 3(5):1068-74. PubMed ID: 7339806
    [Abstract] [Full Text] [Related]

  • 3. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei.
    Wallace RJ, Jones DB, Wiss K.
    Rev Infect Dis; 1981 Sep; 3(5):898-904. PubMed ID: 7339821
    [Abstract] [Full Text] [Related]

  • 4. Disseminated Mycobacterium chelonei infection: response to sulfonamides.
    Tice AD, Solomon RJ.
    Am Rev Respir Dis; 1979 Jul; 120(1):197-201. PubMed ID: 464378
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycoside-modifying enzyme assays.
    Wallace RJ, Hull SI, Bobey DG, Price KE, Swenson JM, Steele LC, Christensen L.
    Am Rev Respir Dis; 1985 Aug; 132(2):409-16. PubMed ID: 4026065
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics.
    Stone MS, Wallace RJ, Swenson JM, Thornsberry C, Christensen LA.
    Antimicrob Agents Chemother; 1983 Oct; 24(4):486-93. PubMed ID: 6651277
    [Abstract] [Full Text] [Related]

  • 10. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.
    Woods GL, Bergmann JS, Witebsky FG, Fahle GA, Wanger A, Boulet B, Plaunt M, Brown BA, Wallace RJ.
    J Clin Microbiol; 1999 Jun; 37(6):1676-82. PubMed ID: 10325306
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates.
    Koontz FP, Erwin ME, Barrett MS, Jones RN.
    Diagn Microbiol Infect Dis; 1994 Jul; 19(3):183-6. PubMed ID: 7821001
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial activity of ofloxacin and other agents against mycobacterial isolates from postoperative sternotomy wounds.
    Yew WW, Kwan SY, Ma WK, Lui KS, Aung MK.
    Clin Ther; 1989 Jul; 11(6):775-85. PubMed ID: 2611821
    [Abstract] [Full Text] [Related]

  • 14. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.
    Swenson JM, Wallace RJ, Silcox VA, Thornsberry C.
    Antimicrob Agents Chemother; 1985 Dec; 28(6):807-11. PubMed ID: 4083863
    [Abstract] [Full Text] [Related]

  • 15. Combination of ofloxacin and amikacin in the treatment of sternotomy wound infection.
    Yew WW, Kwan SY, Ma WK, Aung-khin M, Mok CK.
    Chest; 1989 May; 95(5):1051-5. PubMed ID: 2707062
    [Abstract] [Full Text] [Related]

  • 16. Mycobacterium chelonei tenosynovitis.
    Zachary LS, Clark GL, Kleinert JM, O'Donovan C.
    Ann Plast Surg; 1988 Apr; 20(4):360-2. PubMed ID: 3364921
    [Abstract] [Full Text] [Related]

  • 17. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
    Heidarieh P, Mirsaeidi M, Hashemzadeh M, Feizabadi MM, Bostanabad SZ, Nobar MG, Hashemi Shahraki A.
    Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
    [Abstract] [Full Text] [Related]

  • 18. Single daily-dose ofloxacin monotherapy for Mycobacterium fortuitum sternotomy infection.
    Yew WW, Kwan SY, Ma WK, Khin MA, Mok CK.
    Chest; 1989 Nov; 96(5):1150-2. PubMed ID: 2805845
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Topical ciprofloxacin for treating nontuberculous mycobacterial keratitis.
    Hu FR, Luh KT.
    Ophthalmology; 1998 Feb; 105(2):269-72. PubMed ID: 9479286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.